Who
Sara Bonstein
Director
Company insider
Files Form 4 as: Director, Xilio Therapeutics; Chief Financial Officer, Insmed; Director, scPharmaceuticals; CFO/COO, Oncosec Medical; Chief Financial Officer, Advaxis.
In numbers
- Trades disclosed
- 245
- Buys
- 0
- Sells
- 37
- Bought
- $0
- Sold
- $46.5M
- Companies
- 5
- Companies where not an officer
- 2
- First trade
- 1 May 2014
- Last trade
- 11 Jun 2026
- Last filed
- 12 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Jun 2026filed 12 Jun 2026 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | INSM InsmedBiotechnology | SEC FORM 4 Sold | $246K2,404 at $102.27 | filing |
| 3 Jun 2026filed 5 Jun 2026 | INSM InsmedBiotechnology | SEC FORM 4 Sold | $246K2,404 at $102.27 | filing |
| 13 May 2026filed 15 May 2026 | INSM InsmedBiotechnology | SEC FORM 4 Sold | $961K8,272 at $116.18 | filing |
| 13 May 2026filed 15 May 2026 | INSM InsmedBiotechnology | SEC FORM 4 Sold | $961K8,272 at $116.18 | filing |
| 3 Feb 2026filed 4 Feb 2026 | INSM InsmedBiotechnology | SEC FORM 4 Sold | $117K748 at $156.34 | filing |
| 3 Feb 2026filed 4 Feb 2026 | INSM InsmedBiotechnology | SEC FORM 4 Sold | $117K748 at $156.34 | filing |
| 8 Jan 2026filed 8 Jan 2026 | INSM InsmedBiotechnology | SEC FORM 4 Sold | $252K1,447 at $174.17 | filing |
| 8 Jan 2026filed 8 Jan 2026 | INSM InsmedBiotechnology | SEC FORM 4 Sold | $252K1,447 at $174.17 | filing |
| 7 Jan 2026filed 8 Jan 2026 | INSM InsmedBiotechnology | SEC FORM 4 Sold | $294K1,678 at $175.07 | filing |
| 7 Jan 2026filed 8 Jan 2026 | INSM InsmedBiotechnology | SEC FORM 4 Sold | $294K1,678 at $175.07 | filing |
| 6 Jan 2026filed 8 Jan 2026 | INSM InsmedBiotechnology | SEC FORM 4 Sold | $263K1,517 at $173.33 | filing |
| 6 Jan 2026filed 8 Jan 2026 | INSM InsmedBiotechnology | SEC FORM 4 Sold | $263K1,517 at $173.33 | filing |
| 2 Jan 2026filed 6 Jan 2026 | INSM InsmedBiotechnology | SEC FORM 4 Code A | —5,998 | filing |
| 2 Jan 2026filed 6 Jan 2026 | INSM InsmedBiotechnology | SEC FORM 4 Code A | —5,645 | filing |
| 2 Jan 2026filed 6 Jan 2026 | INSM Insmedoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,280 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | INSM Insmedoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,280 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | INSM InsmedBiotechnology | SEC FORM 4 Code A | —5,998 | filing |
| 2 Jan 2026filed 6 Jan 2026 | INSM InsmedBiotechnology | SEC FORM 4 Code A | —5,645 | filing |
News
No headline names them, or the companies they trade most, lately.